Pitcairn Co. Sells 2,036 Shares of West Pharmaceutical Services, Inc. $WST

Pitcairn Co. reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 23.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,601 shares of the medical instruments supplier’s stock after selling 2,036 shares during the quarter. Pitcairn Co.’s holdings in West Pharmaceutical Services were worth $1,732,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of West Pharmaceutical Services by 193.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 95 shares during the last quarter. SJS Investment Consulting Inc. raised its stake in shares of West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 129 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in West Pharmaceutical Services during the third quarter valued at approximately $47,000. Finally, MUFG Securities EMEA plc acquired a new stake in West Pharmaceutical Services in the second quarter valued at approximately $47,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $245.92 on Friday. The stock has a 50-day moving average of $253.72 and a two-hundred day moving average of $262.03. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $322.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The stock has a market cap of $17.71 billion, a P/E ratio of 36.22, a P/E/G ratio of 2.59 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business had revenue of $805.00 million for the quarter, compared to analyst estimates of $795.70 million. During the same period in the prior year, the company earned $1.82 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services declared that its Board of Directors has initiated a stock buyback program on Tuesday, February 17th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is 12.96%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. UBS Group reaffirmed a “buy” rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. Barclays decreased their price target on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating for the company in a research note on Friday, February 13th. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Evercore cut their price objective on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $314.56.

West Pharmaceutical Services News Summary

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.